Inovio Pharmaceuticals Inc (INO) - Net Assets
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has net assets worth $-7.72 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($69.39 Million) and total liabilities ($77.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check INO financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.72 Million |
| % of Total Assets | -11.13% |
| Annual Growth Rate | 8.46% |
| 5-Year Change | -85.14% |
| 10-Year Change | -61.06% |
| Growth Volatility | 1620.6 |
Inovio Pharmaceuticals Inc - Net Assets Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore INO asset base for the complete picture of this company's asset base.
Annual Net Assets for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual net assets of Inovio Pharmaceuticals Inc from 1998 to 2024. For live valuation and market cap data, see market value of Inovio Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $68.50 Million | -41.62% |
| 2023-12-31 | $117.35 Million | -47.23% |
| 2022-12-31 | $222.36 Million | -44.36% |
| 2021-12-31 | $399.67 Million | -13.33% |
| 2020-12-31 | $461.14 Million | +8431.97% |
| 2019-12-31 | $5.40 Million | -93.79% |
| 2018-12-31 | $87.03 Million | -38.92% |
| 2017-12-31 | $142.49 Million | +15.49% |
| 2016-12-31 | $123.38 Million | -29.87% |
| 2015-12-31 | $175.93 Million | +57.73% |
| 2014-12-31 | $111.54 Million | +110.84% |
| 2013-12-31 | $52.90 Million | +51.77% |
| 2012-12-31 | $34.86 Million | -27.17% |
| 2011-12-31 | $47.86 Million | +1.62% |
| 2010-12-31 | $47.10 Million | -23.02% |
| 2009-12-31 | $61.18 Million | +220.24% |
| 2008-12-31 | $19.11 Million | -38.44% |
| 2007-12-31 | $31.03 Million | +32.05% |
| 2006-12-31 | $23.50 Million | +0.13% |
| 2005-12-31 | $23.47 Million | +50.94% |
| 2004-12-31 | $15.55 Million | +3.34% |
| 2003-12-31 | $15.05 Million | +303.92% |
| 2002-12-31 | $3.73 Million | -24.94% |
| 2001-12-31 | $4.96 Million | -49.82% |
| 2000-12-31 | $9.89 Million | -16.41% |
| 1999-12-31 | $11.83 Million | +42.54% |
| 1998-12-31 | $8.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inovio Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 171021926200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $36.10K | 0.05% |
| Other Comprehensive Income | $-675.67K | -0.99% |
| Other Components | $1.80 Billion | 2626.66% |
| Total Equity | $68.50 Million | 100.00% |
Inovio Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Billion Electric Co Ltd
TW:3027
|
$75.58 Million |
|
QPM Energy Ltd
AU:QPM
|
$75.61 Million |
|
Hana Must SPAC 2
KQ:208370
|
$75.64 Million |
|
Ak Holdings
KO:006840
|
$75.68 Million |
|
United Polyfab Gujarat Limited
NSE:UNITEDPOLY
|
$75.56 Million |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
$75.51 Million |
|
Apollo Power Ltd
TA:APLP
|
$75.51 Million |
|
Yusin Holding Corp
TW:4557
|
$75.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inovio Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 117,349,129 to 68,503,795, a change of -48,845,334 (-41.6%).
- Net loss of 107,254,126 reduced equity.
- New share issuances of 36,033,473 increased equity.
- Other comprehensive income decreased equity by 13,066.
- Other factors increased equity by 22,388,385.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-107.25 Million | -156.57% |
| Share Issuances | $36.03 Million | +52.6% |
| Other Comprehensive Income | $-13.07K | -0.02% |
| Other Changes | $22.39 Million | +32.68% |
| Total Change | $- | -41.62% |
Book Value vs Market Value Analysis
This analysis compares Inovio Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.17x to 0.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $6.55 | $1.10 | x |
| 1999-12-31 | $9.34 | $1.10 | x |
| 2000-12-31 | $7.01 | $1.10 | x |
| 2001-12-31 | $2.87 | $1.10 | x |
| 2002-12-31 | $1.47 | $1.10 | x |
| 2003-12-31 | $4.52 | $1.10 | x |
| 2004-12-31 | $3.53 | $1.10 | x |
| 2005-12-31 | $4.94 | $1.10 | x |
| 2006-12-31 | $2.30 | $1.10 | x |
| 2007-12-31 | $2.99 | $1.10 | x |
| 2008-12-31 | $1.74 | $1.10 | x |
| 2009-12-31 | $3.24 | $1.10 | x |
| 2010-12-31 | $1.80 | $1.10 | x |
| 2011-12-31 | $1.50 | $1.10 | x |
| 2012-12-31 | $1.01 | $1.10 | x |
| 2013-12-31 | $1.14 | $1.10 | x |
| 2014-12-31 | $1.87 | $1.10 | x |
| 2015-12-31 | $2.57 | $1.10 | x |
| 2016-12-31 | $1.68 | $1.10 | x |
| 2017-12-31 | $1.74 | $1.10 | x |
| 2018-12-31 | $0.94 | $1.10 | x |
| 2019-12-31 | $0.03 | $1.10 | x |
| 2020-12-31 | $2.71 | $1.10 | x |
| 2021-12-31 | $1.86 | $1.10 | x |
| 2022-12-31 | $11.18 | $1.10 | x |
| 2023-12-31 | $5.29 | $1.10 | x |
| 2024-12-31 | $2.52 | $1.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inovio Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49254.27%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.65x
- Recent ROE (-156.57%) is above the historical average (-202.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -79.52% | -79.52% | 0.85x | 1.18x | $-7.43 Million |
| 1999 | -55.78% | -79.52% | 0.59x | 1.18x | $-7.78 Million |
| 2000 | -97.06% | -189.07% | 0.44x | 1.16x | $-10.59 Million |
| 2001 | -178.65% | -199.11% | 0.67x | 1.34x | $-9.36 Million |
| 2002 | -160.11% | -3147.32% | 0.03x | 1.45x | $-6.34 Million |
| 2003 | -31.00% | -5792.83% | 0.00x | 1.08x | $-6.17 Million |
| 2004 | -70.57% | -940.19% | 0.06x | 1.35x | $-12.53 Million |
| 2005 | -65.17% | -279.79% | 0.19x | 1.23x | $-17.64 Million |
| 2006 | -68.75% | -359.82% | 0.10x | 1.98x | $-14.29 Million |
| 2007 | -36.10% | -233.05% | 0.12x | 1.28x | $-14.31 Million |
| 2008 | -67.86% | -618.11% | 0.05x | 2.04x | $-14.88 Million |
| 2009 | -40.31% | -267.67% | 0.11x | 1.33x | $-30.47 Million |
| 2010 | -37.88% | -286.65% | 0.11x | 1.21x | $-22.26 Million |
| 2011 | -32.24% | -155.72% | 0.16x | 1.29x | $-19.98 Million |
| 2012 | -57.25% | -477.56% | 0.09x | 1.31x | $-23.10 Million |
| 2013 | -125.88% | -490.29% | 0.15x | 1.68x | $-71.27 Million |
| 2014 | -32.48% | -345.44% | 0.08x | 1.18x | $-47.24 Million |
| 2015 | -16.61% | -71.94% | 0.19x | 1.22x | $-46.76 Million |
| 2016 | -59.81% | -208.49% | 0.20x | 1.41x | $-86.07 Million |
| 2017 | -61.95% | -208.92% | 0.23x | 1.31x | $-102.45 Million |
| 2018 | -111.54% | -318.12% | 0.23x | 1.51x | $-105.66 Million |
| 2019 | -3474.70% | -2902.75% | 0.03x | 41.91x | $-119.70 Million |
| 2020 | -36.09% | -2245.39% | 0.01x | 1.17x | $-212.53 Million |
| 2021 | -75.98% | -17109.87% | 0.00x | 1.24x | $-343.63 Million |
| 2022 | -125.84% | -2726.67% | 0.03x | 1.57x | $-302.05 Million |
| 2023 | -115.14% | -16239.87% | 0.00x | 1.46x | $-146.85 Million |
| 2024 | -156.57% | -49254.27% | 0.00x | 1.65x | $-114.10 Million |
Industry Comparison
This section compares Inovio Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inovio Pharmaceuticals Inc (INO) | $-7.72 Million | -79.52% | N/A | $75.57 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more